Human Growth Hormone Increases SMN Expression and Survival in Severe Spinal Muscular Atrophy Mouse Model

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Neuromuscular Diseases

• Publication date

  2014-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3233/JND-140000PMID 27858661
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study.

  2014influential reference
• Spinal Muscular Atrophy: Classification, Diagnosis, Background, Molecular Mechanism and Development of Therapeutics

  2013cited by this paper
• Effects of insulin and IGF-I on growth hormone- induced STAT5 activation in 3T3-F442A adipocytes

  2013cited by this paper
• Celecoxib increases SMN and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation.

  2013cited by this paper
• Glucose metabolism and pancreatic defects in spinal muscular atrophy

  2012cited by this paper
• Motor Neuron Rescue in Spinal Muscular Atrophy Mice Demonstrates That Sensory-Motor Defects Are a Consequence, Not a Cause, of Motor Neuron Dysfunction

  2012cited by this paper
• Survival Motor Neuron Protein in Motor Neurons Determines Synaptic Integrity in Spinal Muscular Atrophy

  2012cited by this paper
• Growth hormone and physical performance.

  2011cited by this paper
• Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice.

  2011cited by this paper
• Peripheral SMN restoration is essential for long-term rescue of a severe SMA mouse model

  2011cited by this paper
• Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimens

  2011cited by this paper
• Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN

  2011cited by this paper
• Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathway.

  2011influential reference
• Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy.

  2011cited by this paper
• Cardiac defects contribute to the pathology of spinal muscular atrophy models.

  2010cited by this paper
• Digital necroses and vascular thrombosis in severe spinal muscular atrophy

  2010cited by this paper
• The growth hormone receptor: mechanism of activation and clinical implications

  2010influential reference
• Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery.

  2010cited by this paper
• Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice.

  2010cited by this paper
• Recombinant human prolactin for the treatment of lactation insufficiency

  2010cited by this paper
• therapeutic strategies

  2010cited by this paper
• Impact of GH substitution on exercise capacity and muscle strength in GH‐deficient adults: a meta‐analysis of blinded, placebo‐controlled trials

  2009cited by this paper
• Different atrophy-hypertrophy transcription pathways in muscles affected by severe and mild spinal muscular atrophy

  2009cited by this paper
• Vascular perfusion abnormalities in infants with spinal muscular atrophy.

  2009cited by this paper
• p38 Mitogen-activated protein kinase stabilizes SMN mRNA through RNA binding protein HuR.

  2009cited by this paper
• DcpS as a therapeutic target for spinal muscular atrophy.

  2008cited by this paper
• Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy.

  2007cited by this paper
• Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy

  2007cited by this paper
• Stat5 constitutive activation rescues defects in spinal muscular atrophy.

  2007cited by this paper
• SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN.

  2005influential reference
• Role of insulin-like growth factor I signaling in neurodegenerative diseases

  2004cited by this paper
• Correlation between SMN2 copy number and clinical phenotype of spinal muscular atrophy: three SMN2 copies fail to rescue some patients from the disease severity

  2002cited by this paper
• Mouse model of spinal muscular atrophy.

  2000cited by this paper
• Continuation of growth hormone (GH) replacement in GH-deficient patients during transition from childhood to adulthood: a two-year placebo-controlled study.

  2000cited by this paper
• A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy.

  1999cited by this paper
• A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2.

  1999cited by this paper
• Functional Roles of STAT Family Proteins: Lessons from Knockout Mice

  1999influential reference
• Measures of submaximal aerobic performance evaluate and predict functional response to growth hormone (GH) treatment in GH-deficient adults.

  1999cited by this paper
• Activation of the Jak2-Stat5 Signaling Pathway in Nb2 Lymphoma Cells by an Anti-apoptotic Agent, Aurintricarboxylic Acid*

  1998influential reference
• Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos.

  1997influential reference
• Genomic variation and gene conversion in spinal muscular atrophy: implications for disease process and clinical phenotype.

  1997cited by this paper
• Quality of life, body composition and muscle strength in adult growth hormone deficiency: the influence of growth hormone replacement therapy for up to 3 years

  1997cited by this paper
• Identification and characterization of a spinal muscular atrophy-determining gene

  1995cited by this paper
• Mediation of Growth Hormone-dependent Transcriptional Activation by Mammary Gland Factor/Stat 5 (*)

  1995cited by this paper

• Targeted Degradation of mRNA Decapping Enzyme DcpS by a VHL-Recruiting PROTAC.

  2022cites this paper
• Spinal muscular atrophy: Broad disease spectrum and sex-specific phenotypes.

  2021cites this paper
• Effects of growth hormone on cognitive, motor, and behavioral development in Prader-Willi syndrome children: a meta-analysis of randomized controlled trials

  2020cites this paper
• Light modulation ameliorates expression of circadian genes and disease progression in spinal muscular atrophy mice

  2018cites this paper
• Degenerative Neurological and Neuromuscular Disease Dovepress Current and Emerging Treatment Options for Spinal Muscular Atrophy

  year unknowncites this paper